Literature DB >> 30554039

Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.

Aditya Banerjee1, Jennifer Ng1, Jessica Coleman1, Juan Pablo Ospina1, Maureen Mealy1, Michael Levy2.   

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) attacks lead to incremental loss of function of the optic nerves and spinal cord. The standard of care for treatment of acute attacks to mitigate damage is high dose corticosteroids and, if needed, plasma exchange. Although the inclination among clinicians is to treat relapses as soon as they start, there is no previously published evidence to conclude that earlier treatment with corticosteroids is more effective in the long term. In this study, we correlated neurological outcomes from acute NMOSD relapses with delay to treatment, as well as demographic and clinical characteristics that influence prognosis.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30554039      PMCID: PMC6397696          DOI: 10.1016/j.msard.2018.12.010

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  4 in total

1.  Contemporary management challenges in seropositive NMOSD.

Authors:  Fiona Costello; Jodie M Burton
Journal:  J Neurol       Date:  2022-07-11       Impact factor: 6.682

2.  Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Jose E Meca-Lallana; Daniel Prefasi; Francisco Pérez-Miralles; Lucía Forero; María Sepúlveda; Carmen Calles; María L Martínez-Ginés; Inés González-Suárez; Sabas Boyero; Lucía Romero-Pinel; Ángel P Sempere; Virginia Meca-Lallana; Luis Querol; Lucienne Costa-Frossard; Hugo de Castro-Trapiello; Neus Canal; Jorge Maurino
Journal:  Patient Prefer Adherence       Date:  2021-04-12       Impact factor: 2.711

Review 3.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

4.  Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

Authors:  Bruce Ac Cree; Jeffrey L Bennett; Ho Jin Kim; Brian G Weinshenker; Sean J Pittock; Dean Wingerchuk; Kazuo Fujihara; Friedemann Paul; Gary R Cutter; Romain Marignier; Ari J Green; Orhan Aktas; Hans-Peter Hartung; Ian M Williams; Jorn Drappa; Dewei She; Daniel Cimbora; William Rees; John N Ratchford; Eliezer Katz
Journal:  Mult Scler       Date:  2021-02-04       Impact factor: 6.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.